{{original research|time=2019-02-04}}

{{medical}}
{{Drugbox
| Verifiedfields = verified
| Watchedfields = verified
| verifiedrevid = 457636058
| IUPAC_name = 2-[(1''R'',6''R'')-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
| image = Cannabidiol.svg
| width = 225px
| image2 = CBD-3D-balls.png
| width2 = 250px

<!--Clinical data-->
| tradename = [[Sativex|Sativex]] (with {{abbrlink|THC|tetrahydrocannabinol}}), [[Epidiolex|Epidiolex]]
| Drugs.com = {{drugs.com|international|cannabidiol}}
| legal_US = Schedule I (except Epidiolex, Schedule V)
| legal_UK = POM
| legal_UK_comment = or Dietary Supplement
| legal_AU = S4
| routes_of_administration = [[Route_of_administration#Inhalation|Inhalation]] ([[smoking|smoking]], [[vaping|vaping]]), [[buccal_administration|buccal]] ([[aerosol_spray|aerosol spray]]), [[oral_administration|oral]] ([[solution|solution]])<ref name="SativexLabel">{{cite web|url=https://omr.bayer.ca/omr/online/sativex-pm-en.pdf|title=Sativex (Cannabidiol/Tetrahydrocannabinol) Bayer Label|website=bayer.ca|format=PDF|accessdate=28 June 2018}}</ref><ref name="EpidiolexLabel">{{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf|title=Epidiolex (Cannabidiol) FDA Label|website=fda.gov|format=PDF|accessdate=28 June 2018}} For label updates see [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210365 FDA index page for NDA 210365]</ref>
| class = [[Cannabinoid|Cannabinoid]]

<!--Pharmacokinetic data-->
| bioavailability = • [[Oral_administration|Oral]]: 13–19%<ref name = Mechoulam2002>{{cite journal | vauthors = Mechoulam R, Parker LA, Gallily R | title = Cannabidiol: an overview of some pharmacological aspects | journal = Journal of Clinical Pharmacology | volume = 42 | issue = 11 Suppl | pages = 11S–19S | date = November 2002 | pmid = 12412831 | doi = 10.1002/j.1552-4604.2002.tb05998.x }}</ref><br />• [[Inhalation|Inhaled]]: 31% (11–45%)<ref name=Scuderi2009>{{cite journal | vauthors = Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G | title = Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders | journal = Phytotherapy Research | volume = 23 | issue = 5 | pages = 597–602 | date = May 2009 | pmid = 18844286 | doi = 10.1002/ptr.2625 | type = Review }}</ref>
| protein_bound = 
| metabolism = 
| metabolites = 
| elimination_half-life = 18–32 hours<ref name="devinsky">{{cite journal |last1=Devinsky |first1=Orrin |last2=Cilio |first2=Maria Roberta |last3=Cross |first3=Helen |last4=Fernandez-Ruiz |first4=Javier |last5=French |first5=Jacqueline |last6=Hill |first6=Charlotte |last7=Katz |first7=Russell |last8=Di Marzo |first8=Vincenzo |last9=Jutras-Aswad |first9=Didier |last10=Notcutt |first10=William George |last11=Martinez-Orgado |first11=Jose |last12=Robson |first12=Philip J. |last13=Rohrback |first13=Brian G. |last14=Thiele |first14=Elizabeth |last15=Whalley |first15=Benjamin |last16=Friedman |first16=Daniel |title=Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders |journal=Epilepsia |date=22 May 2014 |volume=55 |issue=6 |pages=791–802 |doi=10.1111/epi.12631|pmc=4707667|pmid=24854329}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 13956-29-1
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 644019
| IUPHAR_ligand = 4150
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 69478
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB09061
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 24593618
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 19GBJ60SN5
| KEGG = D10915
| synonyms = CBD

<!--Chemical data-->
| C=21 | H=30 | O=2
| molecular_weight = 314.464 g/mol
| SMILES = Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h9,12-13,17-18,22-23H,2,5-8,10-11H2,1,3-4H3/t17-,18+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZTGXAWYVTLUPDT-ZWKOTPCHSA-N

<!--Physical data-->
| melting_point = 66
| boiling_point = 
}}
'''大麻二酚'''（Cannabidiol，'''CBD'''）是[[大麻|大麻]]百多隻有效成分中最具醫療價值的一種，有保護[[神經|神經]]、改善[[皮膚發炎|皮膚發炎]]、抗氧化、舒緩皮膚敏感泛紅、為[[皮膚表層|皮膚表層]]建立保護屏障、改善皮膚自我修復力；對恢復皮膚健康、舒緩皮膚問題的能力，可以治療[[濕疹|濕疹]]等病

大麻二酚（CBD）是大麻的主要非精神科成分，具有多種藥理作用，包括抗焦慮、抗精神病、止吐和抗炎特性。該綜述根據Web of Science，Scielo和Medline檢索的報告描述了廣泛濃度CBD給藥的多項研究表明，CBD在非轉化細胞中無毒性，不會誘發食物攝入變化，不會誘發全身僵硬症，不會影響生理參數（心率、血壓和體溫），不會影響胃腸道的轉運和不會改變精神運動或心理功能。

研究報告指出，長期使用和高劑量 (高達1,500毫克/天) 的CBD在人體內耐受性仍然良好。儘管CBD與THC具有分子相似性，CBD僅在非常高劑量（THC的100倍）下才與大麻素受體有相互弱作用性。另外，在CBD中亦未察覺到如THC般會引起對人體思維和感知的改變。不同藥理學性質使CBD與THC具有完全不一樣的安全性。

對25項關於生物多樣性公約內安全性和功效研究的綜述，並未發現CBD於廣泛劑量範圍中使用多種給藥方式有顯著副作用，包括急性和慢性給藥方案。CBD已在歐洲大部分地區和其他國家獲得安全性和功效批准。因此，有關它的新陳代謝，毒理學和安全性巳在醫學上具有廣泛的信息。

==參考資料==
{{reflist}}

[[Category:未分配ATC的藥物|Category:未分配ATC的藥物]]
[[Category:血清素受体激动剂|Category:血清素受体激动剂]]
[[Category:抗炎药|Category:抗炎药]]
[[Category:抗痉挛药物|Category:抗痉挛药物]]
[[Category:大麻素|Category:大麻素]]
[[Category:環己烯|Category:環己烯]]
[[Category:天然酚|Category:天然酚]]
[[Category:间苯二酚|Category:间苯二酚]]